The imaging and advanced guidance for workflow optimization in interventional oncology consortium (IMAGIO) consortium of clinical partners in the EU, led by Royal Philips NV, has been awarded $26 million under the Innovative Health Initiative (IHI) to carry out research into less invasive cancer therapies.
Aegis Life Inc. and its parent company Entos Pharmaceuticals Inc. (Entos) have entered into a grant agreement with the Bill & Melinda Gates Foundation in the area of infectious disease.
Amplo Biotechnology Inc. has been awarded a fast track phase I/II Small Business Technology Transfer (STTR) grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health (NIH) to fund further development of AMP-201, an AAV-ColQ gene therapy designed to address congenital myasthenic syndrome caused by collagen Q (ColQ) deficiency.
Senisca Ltd. has been awarded a £571,350 (US$712,000) grant from Innovate UK toward the development of oligonucleotide therapeutics for the treatment of idiopathic pulmonary fibrosis (IPF).
Vesigen Therapeutics Inc. has been awarded a grant by the Friedreich’s Ataxia Research Alliance (FARA) to develop a targeted genome editing therapeutic strategy for Friedreich’s ataxia.
Olatec Therapeutics LLC has been awarded a research grant by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to evaluate its lead molecule, dapansutrile (OLT-1177), in preclinical Parkinson’s disease progression models.
RSS
